FDA Expands Vemlidy Use to Adolescents With Chronic HBV FDA Expands Vemlidy Use to Adolescents With Chronic HBV

The indication for the nucleoside analog reverse transcriptase inhibitor in children aged 12 years and older is based on safety and efficacy data from a placebo-controlled clinical trial.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Gastroenterology News Alert Source Type: news